Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Axovant Sciences Ltd (AXGT)

Axovant Sciences Ltd (AXGT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Axovant: Fiscal Q3 Earnings Snapshot AP - Tue Feb 14, 2023

Axovant: Fiscal Q3 Earnings Snapshot

AXGT : 2.10 (-2.33%)
Axovant: Fiscal Q3 Earnings Snapshot AP - Fri Feb 11, 2022

NEW YORK (AP) _ Axovant Sciences Ltd. (SIOX) on Friday reported a loss of $25.5 million in its fiscal third quarter.

AXGT : 2.10 (-2.33%)
Axovant: Fiscal Q2 Earnings Snapshot AP - Fri Nov 12, 2021

NEW YORK (AP) _ Axovant Sciences Ltd. (SIOX) on Friday reported a loss of $21.2 million in its fiscal second quarter.

AXGT : 2.10 (-2.33%)
Sio Gene Therapies Announces First Patient Dosed in High-Dose Cohort of AXO-AAV-GM1 Clinical Trial in Patients with GM1 Gangliosidosis Globe NewsWire - Wed Dec 2, 2020

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform...

AXGT : 2.10 (-2.33%)
SIOX : 0.4780 (+1.70%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sio Gene Therapies, Inc. – AXGT Globe NewsWire - Mon Nov 30, 2020

NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sio Gene Therapies, Inc. (“Sio” or the “Company”) (NASDAQ: AXGT). Such investors...

AXGT : 2.10 (-2.33%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axovant Gene Therapies Ltd. - AXGT Globe NewsWire - Wed Nov 25, 2020

NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Axovant Gene Therapies Ltd. (“Axovant” or the “Company”) (NASDAQ: AXGT). Such investors...

AXGT : 2.10 (-2.33%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axovant Gene Therapies Ltd. - AXGT Globe NewsWire - Sat Nov 21, 2020

NEW YORK, Nov. 21, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Axovant Gene Therapies Ltd. (“Axovant” or the “Company”) (NASDAQ: AXGT).   Such investors...

AXGT : 2.10 (-2.33%)
Sio Gene Therapies Appoints Gene Therapy Pioneer Guangping Gao, Ph.D., as Chief AAV Scientific Advisor Globe NewsWire - Thu Nov 19, 2020

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform...

AXGT : 2.10 (-2.33%)
SIOX : 0.4780 (+1.70%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axovant Gene Therapies Ltd. - AXGT Globe NewsWire - Mon Nov 16, 2020

NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Axovant Gene Therapies Ltd. (“Axovant” or the “Company”) (NASDAQ: AXGT).   Such investors...

AXGT : 2.10 (-2.33%)
Sio Gene Therapies Announces Corporate Updates and Financial Results for Second Fiscal Quarter Ended September 30, 2020 Globe NewsWire - Fri Nov 13, 2020

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform...

AXGT : 2.10 (-2.33%)
SIOX : 0.4780 (+1.70%)

Barchart Exclusives

Stocks Plunge Before the Open as Meta’s Revenue Forecast Disappoints, U.S. GDP Data and Earnings in Focus Barchart - 1 hour ago
June S&P 500 E-Mini futures (ESM24) are down -0.53%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.87% this morning as a disappointing revenue outlook for the current quarter from Meta weighed on sentiment, while market participants braced for a new round of U.S. economic data and quarterly reports from heavyweight names. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot